Gain Therapeutics, Inc. (GANX): Price and Financial Metrics


Gain Therapeutics, Inc. (GANX): $2.89

0.17 (+6.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GANX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GANX Stock Price Chart Interactive Chart >

Price chart for GANX

GANX Price/Volume Stats

Current price $2.89 52-week high $10.90
Prev. close $2.72 52-week low $2.33
Day low $2.71 Volume 91,700
Day high $2.94 Avg. volume 118,818
50-day MA $3.56 Dividend yield N/A
200-day MA $5.53 Market Cap 34.34M

Gain Therapeutics, Inc. (GANX) Company Bio


Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.


GANX Latest News Stream


Event/Time News Detail
Loading, please wait...

GANX Latest Social Stream


Loading social stream, please wait...

View Full GANX Social Stream

Latest GANX News From Around the Web

Below are the latest news stories about Gain Therapeutics Inc that investors may wish to consider to help them evaluate GANX as an investment opportunity.

B.Riley Financial Keeps Their Buy Rating on Gain Therapeutics (GANX)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) today and set a price target of $21.00. The company's shares closed last Friday at $4.04, close to its 52-week low of $3.71. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -18.7% and a 29.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gain Therapeutics with a $25.50 average price target.

Brian Anderson on TipRanks | February 11, 2022

Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022

Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functionsBETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data

Yahoo | February 8, 2022

Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day

BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today held its inaugural research and development day webinar. Capitalizing on significant advances in computational biology and drug discovery, the Company has applied its proprietary computational S

Yahoo | February 4, 2022

Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the UndruggableBETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced additional details on its R&D Day being held virtually on Friday, February 4, 2022 from 10:00 am

Yahoo | January 31, 2022

Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences

- Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable - - 18 th Annual WORLDSymposium - AD/PD 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX ) ("Gain"), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D Day Event and participating in upcoming scientific conferences. Please see additional details below: R&D Day Event and Conferences Save-the-Date Details: Event: Neuroscience and Beyond: Harnessing Computational Technology Full story available on Benzinga.com

Benzinga | January 18, 2022

Read More 'GANX' Stories Here

GANX Price Returns

1-mo -17.66%
3-mo -13.99%
6-mo -62.07%
1-year -72.71%
3-year N/A
5-year N/A
YTD -46.78%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7387 seconds.